SBSteven Birken

Steven Birken

*This is an algorithmically generated author record based on publicly available information.

Steven Birken has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Specific Measurement of O-Linked Core 2 Sugar-Containing Isoforms of Hyperglycosylated Human Chorionic Gonadotropin by Antibody B152

    by Steven Birken

    There have been a significant number of reports on the clinical utility of measurement of 'hyperglycosylated' isoforms of the pregnancy hormone, human chorionic gonadotropin (hCG). Although there are a variety of hCG isoforms which can be termed 'hyperglycosylated', the measurements were all made using a unique antibody designated B152. This antibody was raised using a choriocarcinoma-derived form of hCG, which was hyperglycosylated with N- and O-glycans and was also 100% 'nicked' hCG. Antibody B152 was recently mapped to a linear epitope around a single O-glycan on the beta-subunit of hCG at residue number 132. Thus, the antibody can only measure isoforms of hCG that possess a core 2 type of branched O-glycan on this portion of the hCG beta-subunit. Isoforms that are hyperglycosylated in the hCG alpha-subunit or only on the N-glycans of hCGbeta will not be recognized by antibody B152. Apparently, measurements of these core 2 hCG isoforms have important clinical application in early pregnancy during which they are the predominant isoform of hCG until the 6th week of gestation. The secretory pattern of these isoforms can be used to predict the health status of the pregnancy in fertility clinics. Moreover, the measurements of these core 2 hCG isoforms are more useful than standard hCG for the prediction of Down syndrome pregnancies. The core 2 isoforms are also of important use in cancer diagnosis and monitoring since their concentration appears to correlate with malignancy.


  • Open Access

    Preparation and Characterization of New WHO Reference Reagents for Human Chorionic Gonadotropin and Metabolites

    by Steven Birken, Peter Berger, Jean-Michel Bidart, Matthias Weber, Adrian Bristow, Rob Norman, Catharine Sturgeon, Ulf-Håkan Stenman

    Background: The currently used standards for human chorionic gonadotropin (hCG) and its α and β subunits (hCGα and hCGβ) contain substantial amounts of contaminating variants of hCG and other impurities. Furthermore, some partially degraded forms of hCG and its subunits have become of potential clinical importance, e.g., “nicked” forms of hCG (hCGn) and hCGβ (hCGβn), which contain cuts in the peptide backbone between amino acids 44–45 or 47–48 in hCGβ, and a fragment of hCGβ (hCGβcf) consisting of amino acids 6–40 and 55–92 bound together by disulfide bridges. The IFCC appointed a working group with the aim of preparing new standards for hCG and related substances to improve standardization of their immunoassays. Methods: Large amounts of hCG and its subunits as well as of hCGn, hCGβn, and hCGβcf were prepared by previously developed purification methods in combination with hydrophobic interaction chromatography and reversed-phase HPLC. Each preparation was characterized on the basis of amino acid and sequence analyses, carbohydrate composition, and electrophoretic patterns. Immunoassays for relevant contaminating proteins were also performed. Results: The major preparations were homogeneous and free of contaminating proteins. Concentrations of the final preparations were determined by amino acid analysis. Conclusions: Calibrated in substance concentrations (mol/L) based on amino acid analyses, these preparations will facilitate improved standardization of immunoassays for hCG and its metabolites. The six preparations have now been established by the WHO as new 1st Reference Reagents for immunoassays with the following codes: hCG 99/688, hCGβ 99/650, hCGα 99/720, hCGn 99/642, hCGβn 99/692, and hCGβcf 99/708. In contrast to the 3rd International Standard (75/537), the clinically most important Reference Reagent for hCG (99/688) contains no hCGn and negligible amounts of free subunits.


  • Immunochemical Measurement of Early Pregnancy Isoforms of hCG

    by Steven Birken, Galina Kovalevskaya, John O'COnnor


  • Open Access

    Metabolism of gonadotropins: comparisons of the primary structures of the human pituitary and urinary LH beta cores and the chimpanzee CG beta core demonstrate universality of core production

    by S Birken, Ma Gawinowicz, Y Maydelman, Y Milgrom

    The gonadotropins are a family of closely related heterodimeric glycoprotein hormones homologous in structure to disulfide-knot growth factors. Metabolic proteolytic processing in vivo of this disulfide cross-linked region results in urinary excretion of a residual highly stable core structure. The primary structure of the pituitary form of the hLH beta core was reported earlier, but it has proved difficult to isolate the urinary core, although antibodies to the pituitary core demonstrated its presence. By conventional and immunoaffinity methods, the urinary core has been isolated and its structure determined by both chemical and mass spectrometric methods. The urinary hLH beta core is the same as the pituitary-extracted hLH beta core, beta 6-40 disulfide bridged to beta 55-93, except that the pituitary core is more heterogeneous containing also beta 49-93. These findings imply a dual origin of urinary cores, both directly from a secreting tissue and by kidney processing of circulating hormone. We also found that pregnant chimpanzees excrete a CG beta core with a primary structure identical to that of the human CG beta core of pregnancy. In conclusion, gonadotropin core generation and urinary excretion of nearly identical gonadotropin metabolites is common among primates. Although possible biological functions of these core fragments remain unproven, they have diagnostic utility because of their stability and abundance.


  • Open Access

    Preparation and Analysis of the Common Urinary Forms of Human Chorionic Gonadotropin

    by Steven Birken, Yacov Maydelman, Mary Ann Gawinowicz


  • Development and Characterization of Antibodies to a Nicked and Hyperglycosylated Form of hCG from a Choriocarcinoma Patient: Generation of Antibodies That Differentiate Between Pregnancy hCG and Choriocarcinoma hCG

    by Steven Birken, Alexander Krichevsky, John O'Connor, John Schlatterer, Laurence Cole, Andrew Kardana, Robert Canfield

    Human chorionic gonadotropin (hCG) exists in blood and urine as a variety of isoforms one of which contains peptide bond cleavages within its β-subunit loop 2 and is referred to as nicked hCG (hCGn). This hCG isoform appears to be more prevalent in the urine of patients with certain malignancies and possibly in some disorders of pregnancy. Until now, only indirect immunoassays could be used to quantify hCGn. We report the development of two monoclonal antibodies (MAbs) to a form of hCGn isolated from a choriocarcinoma patient. This hCG isoform was not only 100% nicked, but also contained 100% tetrasaccharide-core O-linked carbohydrate moieties in its β COOH-terminal region. Two-site immunometric assays have been developedusing these new antibodies, B151 and B152. The former exhibits good specificity for hCGn independent of the source of the hCGn, the form excreted by choriocarcinoma patients or the form of hCGn from normal pregnancies. The latter antibody, B152, is sensitive to the carbohydrate moieties and possibly other differences in hCG isoforms, but is not for nicking of the β-subunit. These two immunometric assays provide potential novel diagnostic tools for direct measurement of hCG isoforms which could not be accurately quantified earlier before development of the assays using these newly generated antibodies.


  • Development, characterization, and application of monoclonal antibodies to the native and synthetic beta COOH-terminal portion of human chorionic gonadotropin (hCG) that distinguish between the native and desialylated forms of hCG.

    by A Krichevsky, S Birken, J O'Connor, H F Acevedo, K Bikel, J Lustbader, A Hartree, R E Canfield

    Although the pregnancy hormone hCG has been extensively mapped immunochemically, few monoclonal antibodies have been produced to the unique COOH-terminal region of its beta-subunit (beta CTP). We now report the development and characterization of five such monoclonal antibodies. Three of these antibodies were developed to the synthetic peptide analog of the hCG beta-(109-145) region coupled to diphtheria toxoid, and two antibodies to a conjugate of bovine thyroglobulin and the peptide hCG beta-(115-145) prepared from hCG with its carbohydrate moieties intact. The monoclonal antibodies raised against the synthetic peptide bound hCG, desialylated hCG, and synthetic peptide to a similar extent, whereas antibodies generated to the natural hCG peptide did not bind to the synthetic peptide analog of the COOH-terminal peptide (beta CTP) region or to desialyated hCG. These new monoclonal antibodies could distinguish between native and desialyated hCG in liquid phase immunoassays as well as by Western blots. They are highly specific reagents for such Western blotting and were used for studies of a crude human pituitary gonadotropin preparation to demonstrate that it contained intact hCG beta without the internal peptide bond cleavages found in the subunit present in human blood and urine. Competition experiments using combinations of monoclonal antibodies and rabbit anti-beta CTP antiserum demonstrated that two epitopes exist within the beta-(115-145) region of hCG, one of which depends on the presence of carbohydrate. In summary, the new monoclonal hCG beta CTP antibodies reported here can 1) discriminate between native and desialylated hCG, 2) identify hCG and nicked hCG on Western blots, 3) provide an immunoaffinity purification tool for hCG, and 4) bind to two distinct epitopes on the beta CTP.


    • 1 January 1993
      • Vol. 216, 42-78

    Standardization of protein immunoprocedures. Choriogonadotropin (CG).

    by U H Stenman, J M Bidart, S Birken, K Mann, B Nisula, J O'Connor

    The objectives of this report is to improve the quality of immunochemical determinations of proteins. Procedures for determination of the various molecular forms hCG were chosen as the subject of a detailed study, with the aim as using this report as a model for similar future projects. The aim of this undertaking is to improve the reliability and reproducibility of the results and, as a result of this, to enhance the clinical usefulness of hCG determinations. The following means will be used to achieve these goals: (a) establishing uniform nomenclature and abbreviations for various molecular forms of hCG, (b) preparation of new calibrators for these and establishing of methods for determining the amount of substance concentration in mol/L, (c) improving quality assessment materials and procedures, (d) definition of methods for characterization of hCG measurement procedures.